Marker Therapeutics ( (MRKR) ) has provided an announcement.
Marker Therapeutics announced significant progress in 2024, particularly with their lead program, MT-601, which showed promising safety and efficacy in treating refractory lymphomas in the Phase 1 APOLLO study. The company secured over $13 million in non-dilutive funding to support its clinical programs and received approval for the nonproprietary name ‘neldaleucel’ for MT-601. These advancements, along with strategic financing, position Marker Therapeutics to continue its momentum into 2025, focusing on cash preservation and disciplined execution to maximize the impact of its clinical programs.
More about Marker Therapeutics
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors.
YTD Price Performance: -60.06%
Average Trading Volume: 134,851
Technical Sentiment Signal: Buy
Current Market Cap: $13.6M
For an in-depth examination of MRKR stock, go to TipRanks’ Stock Analysis page.